Jiangsu Nhwa Pharmaceutical Co., LTD Stock

Equities

002262

CNE100000CG8

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-07-18 pm EDT 5-day change 1st Jan Change
23.35 CNY -0.76% Intraday chart for Jiangsu Nhwa Pharmaceutical Co., LTD +4.71% -13.90%
Sales 2024 * 5.95B 819M Sales 2025 * 7.16B 985M Capitalization 23.53B 3.24B
Net income 2024 * 1.23B 169M Net income 2025 * 1.53B 210M EV / Sales 2024 * 3.44 x
Net cash position 2024 * 3.04B 418M Net cash position 2025 * 3.99B 549M EV / Sales 2025 * 2.73 x
P/E ratio 2024 *
19.2 x
P/E ratio 2025 *
15.4 x
Employees 5,394
Yield 2024 *
1.26%
Yield 2025 *
0.9%
Free-Float 48.19%
More Fundamentals * Estimated data
Dynamic Chart
Nhwa Pharmaceutical's Penehyclidine Hydrochloride Injection Passes Regulatory Testing MT
Nhwa Pharmaceutical Gets Registration Certificate for Pregabalin Capsules MT
Nhwa Pharma Gets China Nod to Register Epilepsy Drug MT
Jiangsu Nhwa Pharmaceutical Co., Ltd Approves Cash Dividend for 2023, Payable on 15 May 2024 CI
Jiangsu Nhwa Pharmaceutical Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Nhwa Pharma Gets Nod to Test NH103 Oxalate Tablets MT
Jiangsu Nhwa Pharmaceutical Co., Ltd Proposes Profit Distribution for 2023 CI
Nhwa Pharmaceutical's 2023 Profit Climbs 15% as Revenue Rises 17% MT
Jiangsu Nhwa Pharmaceutical Co., LTD Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Exchange-Traded Funds Higher, Equity Futures Lower Pre-Bell Monday Ahead of Data-Packed Week MT
Teva Pharmaceutical Investments Singapore Pte Ltd. and Jiangsu Nhwa Pharmaceutical Co., LTD Forge Strategic Partnership to Promote Patient Access to Austedo® in China CI
Nhwa Pharmaceutical Gets Green Light from US FDA After Addressing API Deficiencies MT
Jiangsu Nhwa Pharmaceutical Co., LTD Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Beijing Yihua M-Health Technology Co., Ltd. announced that it expects to receive CNY 30 million in funding from Jiangsu Nhwa Pharmaceutical Co., LTD CI
Jiangsu Nhwa Pharmaceutical Co., LTD(XSEC:002262) added to FTSE All-World Index CI
More news
1 day-0.76%
1 week+4.71%
Current month-1.64%
1 month-2.91%
3 months+0.30%
6 months-11.55%
Current year-13.90%
More quotes
1 week
21.90
Extreme 21.9
23.62
1 month
21.90
Extreme 21.9
24.19
Current year
20.64
Extreme 20.64
28.76
1 year
20.64
Extreme 20.64
29.42
3 years
10.97
Extreme 10.97
31.98
5 years
9.91
Extreme 9.91
31.98
10 years
8.25
Extreme 8.25
31.98
More quotes
Managers TitleAgeSince
Chief Executive Officer 47 10-05-25
Director of Finance/CFO 44 22-10-25
Director/Board Member 60 07-04-22
Members of the board TitleAgeSince
Chairman 65 07-04-22
Director/Board Member 63 07-04-22
Director/Board Member 61 07-04-22
More insiders
Date Price Change Volume
24-07-19 23.35 -0.76% 2,464,118
24-07-18 23.53 +3.66% 6,458,498
24-07-17 22.7 +2.07% 5,085,366
24-07-16 22.24 -0.36% 2,637,798
24-07-15 22.32 +0.09% 3,784,580

End-of-day quote Shenzhen S.E., July 18, 2024

More quotes
Jiangsu Nhwa Pharmaceutical Co., LTD is a China-based company principally engaged in the production and sales of pharmaceutical preparations. The Company offers its pharmaceutical products under four categories, which consist of anesthetic medicines, including midazolam injections and etomidate fat emulsion pharmaceutical preparations injections; psychiatric medicines, including risperidone tablets and others; neurological medicines, including gabapentin capsules and others; bulk drugs, including fenofibrate and miconazole nitrate. The Company is also engaged in the pharmaceuticals trading business. Through its subsidiaries, the Company is also engaged in the Internet medical businesses. The Company distributes its products within domestic market and to overseas markets.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
23.35 CNY
Average target price
32.21 CNY
Spread / Average Target
+37.93%
Consensus
  1. Stock Market
  2. Equities
  3. 002262 Stock